Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Journal of Medical Economics|January 17, 2019
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in ChinaWeiting Liao, Jiaxing Huang, David Hutton, et al.
Clinical Breast Cancer|April 14, 2022
Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness AnalysisMingyang Feng, Yang Yang, Weiting Liao, et al.
Frontiers in Public Health|January 27, 2022
Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic ReviewMingyang Feng, Yang Yang, Weiting Liao, et al.
Bioresource Technology|December 23, 2018
Effects of liquefaction parameters of cellulose in supercritical solvents of methanol, ethanol and acetone on products yield and compositionsXin Wang, Xin-An Xie, Jiao Sun, et al.
Frontiers in Pharmacology|April 22, 2022
Comparative Efficacy and Safety of Advanced Intravitreal Therapeutic Agents for Noninfectious Uveitis: A Systematic Review and Network Meta-AnalysisWeiting Liao, Zhenyu Zhong, Guannan Su, et al.
Cancer Management and Research|December 19, 2019
Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal CancerLiangliang Bai, Pengfei Zhang, Kexun Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|September 21, 2020
KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinomaGe Gao, Weiting Liao, Qizhi Ma, et al.
Clinical Therapeutics|September 28, 2020
Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in ChinaQiuji Wu, Pengfei Zhang, Xinyuan Wang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 8, 2021
Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United statesFeng Wen, Hanrui Zheng, Pengfei Zhang, et al.
Frontiers in Oncology|August 28, 2020
Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer From the US and Chinese PerspectivesQiuji Wu, Weiting Liao, Mengxi Zhang, et al.
Pageof 6